Clinical Trial Update: An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

View source ↗

Summary

Expanded-access treatment program for the investigational gene therapy Cretostimogene Grenadanorepvec to treat non-muscle-invasive bladder cancer in patients un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Cretostimogene Grenadanorepvec

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Status: AVAILABLE